Cornea/External Disease News

Neuromodulation and neurostimulation are close cousins, but they are not the same thing.

Artificial tears have long been the first option for patients with dry eye disease, but they only offer a partial solution.

Full-thickness corneal transplants are becoming rarer in the United States, largely because of the overwhelming success of lamellar procedures, especially DSAEK and DMEK.

Ocular surface squamous neoplasia is used to describe neoplastic epithelial abnormalities of the conjunctiva and cornea, ranging from squamous dysplasia to invasive squamous cell carcinoma.

Here it is, at last, the official report of the (not very) momentous (non)randomized (un)controlled clinical trial of “Fauxstasis.”

Treatment-related serious adverse events in ocular safety, the primary endpoints in a 12-month safety clinical trial of reproxalap for the treatment of dry eye disease, were not observed, according to an Aldeyra Therapeutics press release.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Douglas A. Katsev, MD, discusses map-dot-fingerprint dystrophy.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, John D. Sheppard, MD, MMSc, discusses treatment options for patients with concurrent corneal disease and cataracts.

TAMPA, Fla. — In this Healio Video Perspective from the Telling It Like It Is meeting, P. Dee Stephenson, MD, gives an overview of promising options available for presbyopia correction.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Kamran Hosseini, MD, PhD, CEO of Surface Ophthalmics, discusses the company’s programs for its dry eye products.